Desmopressin is a medicine similar to the natural antidiuretic hormone. It is used to reduce excessive urine in diabetes insipidus, for nighttime bedwetting, and in some types of bleeding.
Also known as: DDAVP, Minirin, Desmotabs
Furosemide alters water/electrolyte balance and may increase the risk of sodium disturbances in patients on desmopressin.
Desmopressin reduces free water excretion (hyponatraemia risk); furosemide alters sodium and plasma volume, making fluid/electrolyte balance unpredictable (desmopressin label: monitor Na+).
Serum Na+, weight, urine output, osmolality.
Headache, vomiting, confusion, seizures (hyponatraemia).
Monitor serum sodium in the days after diuretic changes; alert for hyponatraemia symptoms (headache, confusion, nausea).
DailyMed — DDAVP (desmopressin) Tablet/Nasal label [RLD], Warnings (hyponatraemia): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abe23504-ea98-4ed9-9a9a-6db9eaa35251
Carbamazepine potentiates the antidiuretic effect of desmopressin (potentiating ADH secretion/response), increasing the risk of severe hyponatraemia with seizures.
Carbamazepine is a classic SIADH-inducing drug; with desmopressin (an ADH analogue) the water-retaining effect is additive (DDAVP label: avoid drugs promoting abnormal ADH secretion).
Serum Na+, osmolality, weight, neurological status.
Headache, vomiting, confusion, seizures (hyponatraemia).
Avoid co-administration if possible; if needed, serum Na+ 2–3 days after starting/adjusting, fluid restriction and minimum desmopressin dose.
DailyMed — DDAVP (desmopressin) label, Warnings/Drug Interactions (ADH-promoting drugs): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abe23504-ea98-4ed9-9a9a-6db9eaa35251
Paracetamol speeds up desmopressin absorption (higher and earlier peak), transiently and mildly increasing the antidiuretic effect.
Described in the desmopressin label (intranasal/oral): paracetamol increases the absorption rate without changing total bioavailability.
Serum Na+ if chronic combined use in at-risk patients.
Headache, nausea (mild hyponatraemia).
No routine adjustment; in elderly/hyponatraemia-risk patients, reinforce fluid restriction on combined dosing.
DailyMed — DDAVP (desmopressin) Tablet label, Drug Interactions (paracetamol increases absorption rate): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abe23504-ea98-4ed9-9a9a-6db9eaa35251
Alcohol promotes diuresis and blunts desmopressin's antidiuretic effect — it compromises polyuria control; in enuresis, alcohol is discouraged before the dose.
Avoid alcohol in the hours before the dose; respect the 1 h fluid restriction after dosing (DDAVP rule).
DailyMed — DDAVP (desmopressin) § 4.4/5.1 (fluid restriction, hyponatraemia; alcohol promotes diuresis).
Desmopressin increases water retention — contraindicated in established hyponatraemia and at-risk states (SIADH, polydipsia).
Monitor sodium at start and in elderly/children; restrict fluids after the dose.
Site monograph (desmopressin — hyponatraemia); DailyMed DDAVP setid abe23504 (§ 4.4).
Water retention may decompensate HF — caution/contraindication in decompensated HF and poorly controlled hypertension.
Avoid in decompensated HF; monitor weight and symptoms.
EMC-UK — desmopressin SmPC 4.3/4.4 (HF, hypertension).
Annex 1 records "Safety in pregnancy is unknown; it should only be used during pregnancy in cases where the potential benefits justify the risks" (factor C). Note: desmopressin may paradoxically treat gestational diabetes insipidus and maternal von Willebrand disease — in those cases the benefit is clear.
Use only if clearly indicated (central DI, maternal von Willebrand with bleeding); the usual dose is safe regarding the antidiuretic effect — monitor maternal sodium.
Annex 2 records "No useful information available" (l. 42512); desmopressin passes little into milk (peptide) — compatible with caution.
Prontuário Terapêutico INFARMED — Annex 1: "Desmopressin — Safety unknown" (l. 39931-33); Annex 2: "No useful information available" (l. 42512). EMC-UK (MHRA) — Desmopressin SmPC (DDAVP).
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Reduced diuresis (↑ water reabsorption); ↑ factor VIII and von Willebrand (2–4×) within 30–90 min.
Selective renal V2 agonist (little pressor V1 activity): activates adenyl cyclase and aquaporin-2 in the collecting tubule; endothelium releases von Willebrand factor/factor VIII.
Intranasal: 10–20%; oral (sublingual): 0.1%; IV: 100%.
Tissue peptidase degradation (slower than vasopressin); renal excretion.
IV: 1.5–3 h; oral: 3–4 h; intranasal: 3–4 h (effect 8–12 h).
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
